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Abstract: Basal cell carcinoma (BCC) is the most frequent skin cancer, with many different histological sub-
types. Recent studies have investigated the expression of proliferative markers, but little is known about the
expression of metallothioneins (MT) in different histological subtypes of this cancer and their impact on prolif-
eration intensity in BCC. In this study, we examined MT-I/II expression by immunohistochemistry in 58 differ-
ent histological subtypes of BCC (38 nodular, six adenoid, eight infiltrative, and six metatypic cases) and corre-
lated its expression with tumor size and Ki-67 proliferation rate. Statistical analysis revealed no significant dif-
ferences in the expression of studied markers in regard to the histological subtype. A positive correlation be-
tween MT and Ki-67 expression was observed for all the studied cases (r = 0.26; p = 0.049), but was even
stronger in the metatypic subtype of BCC (r = 0.85; p = 0.033). MT and Ki-67 expression did not correlate with
tumor size. In conclusion, it seems that metallothioneins may have an impact on the proliferation rate of BCC,
but further studies are required to determine whether MT may be a risk factor of recurrences. (Folia Histochem-
ica et Cytobiologica 2012, Vol. 50, No. 3, 352–357)
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Introduction
Basal cell carcinoma (BCC, carcinoma basocellulare)
represents a non-uniform group of tumors which are
characterized by slow progression, and the very rare (be-
low 0.1% of cases) development of metastases [1]. BCC
is the most frequent invasive skin tumor in Europe, com-
prising around 80% of non-melanoma skin cancers [2].
In most cases, it involves slowly growing tumors of
a relatively low aggressiveness. A small minority of BCC
leads to relapses and local infiltration of tissue struc-
tures which may lead to death of the host [2].
Depending on histological and clinical traits, more
than ten forms of the tumor can be distinguished [3].
The isolation of individual types of BCC is useful due
to the variable character of its development (variable
aggressiveness), which determines the selection of an
appropriate therapeutic approach [4, 5]. The nodu-
lar and superficial forms manifest no particular ag-
gressiveness and can often be cured. The varieties
manifesting higher aggressiveness and more frequent
recurrences include micronodular, morpheaform,
infiltrative and metatypic types. They may aggressively
infiltrate and destroy surrounding tissues, and in spe-
cific conditions may endanger the patient’s life [6].
The superficial type manifests no particular aggres-
siveness but frequently shows recurrences [5]. Due to
the frequent coexistence of various forms of BCC
within a single lesion and, occasionally, unpredictable
behavior of the tumor, the identification of markers
which are independent of histopathological structure
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but would be helpful in establishing a prognosis, is
urgently needed [2, 5].
Expression of metallothionein (MT) in tumor cells
represents a relatively new prognostic index in vari-
ous neoplastic diseases, as indicated by numerous
studies. MT is a low molecular weight protein (around
7 kDa) which is widely expressed in cells (nuclei and/
/or cytoplasm) of various organs and tumors [6, 7].
Depending on the type, MT consists of 61–68 amino
acids, forming two chains of a and b, linked by a lysine
dimer. Considering their structure and manifestation,
four basic types of MT can be distinguished, includ-
ing MT-I, MT-II, MT-III, MT-IV [6, 7]. Binding of
heavy metal ions, either indispensable for MT func-
tion or toxic, represents a principal character of MT.
The protein plays a protective role, preventing against
intoxication with heavy metals, such as Pb, Hg, Cu,
Cd [8, 9].  MT manifests also a strong anti-oxidative
activity, protecting cells from the damaging effects of
reactive oxygen species, ionizing radiation and che-
motherapeutic agents [10–12]. Intensely dividing cells
(including tumor cells) manifest an increased expres-
sion of MT, which supplies zinc (Zn) ions for enzymes
involved in DNA replication and protects cells from
apoptosis [13]. This has induced investigators to ex-
amine the expression of MT in various tumors [14–
–16]. An increase in MT expression in tumor cells cor-
relates with expression of Ki-67 proliferation antigen
and a less favorable outcome of the disease [6, 7, 14–
–16]. It has been shown that MT-2A isoform expres-
sion in breast cancer cells stimulates cell prolifera-
tion, but does not exert anti-apoptotic properties [17].
Moreover, a decline of MT-I/II expression is associ-
ated with a decrease of PCNA and Ki-67 expression
both in sun-exposed and sun-protected skin, which
may indicate its impact on cell proliferation [18]. It
has been suggested that MT-I/II may protect skin tis-
sues from ultraviolet radiation (UVR) induced car-
cinogenesis on the one hand, but may induce tumor
growth once these occur [19].
Until now, only individual studies have been pub-
lished in which MT expression was studied in skin
cancers [20, 21].  The studies showed an increased
expression of MT in spinocellular carcinoma and
a less typical increased expression of MT in aggres-
sive varieties of BCC, but none of the investigations
dealt with the relationship between expressions of
MT and Ki-67 antigen in various histological types
of BCC.
Our study aimed at determining the intensity of
MT-I/II expressions using the immunohistochemical
method in various histological types of BCC, and cor-
relating its expressions with the expression intensity
of Ki-67 antigen and tumor size.
Material and methods
Patients. Studies were performed on the material of various
histological types of basal cell carcinomas (58 cases) obtained
during excision of the tumor in the Department of Dermatol-
ogy, Venerology and Allergology, Medical University in Wro-
claw between 2005 and 2007. The clinical and pathological data
are summarized in Table 1. The study was approved by the
Commission of Bioethics at Wroclaw Medical University.
Immunohistochemistry. The tumor samples were fixed in
10% buffered formalin, dehydrated and embedded in par-
affin blocks, of which hematoxylin and eosin (HE) stained
slides were made and used for verification of the histopatho-
logical diagnosis. All immunohistochemical reactions (IHC)
were performed on 4-μm-thick paraffin sections mounted
on Superfrost Plus slides (Menzel Gläser, Braunschweig,
Germany). First, sections were deparaffinized in xylene and
rehydrated. In the case of anti-Ki-67 IHC reactions, the sec-
tions were incubated in a citrate buffer (pH 6, 10 mM; 95oC,
20 min) in order to retrieve the antigens. Activity of endog-
enous peroxidase was blocked by 5 min incubation with 3%
solution of H2O2. Expression of MT-I/II and Ki-67 antigen
was demonstrated using mouse monoclonal anti-MT-I/II
(clone E9, dilution 1:100) and anti-Ki-67 (clone MIB-1, di-
lution 1:100) antibodies, respectively. Sections were incu-
bated with primary antibodies overnight at 4oC. The stud-
ied antigens were visualized using biotinylated antibodies
and streptavidin, conjugated with horseradish peroxidase
Table 1. Patient and tumor characteristics
No. of cases (%) Age (years) Tumour diameter [mm]
Mean (range) Mean (range)
BCC 58 (100) 65.98 (21–87) 20.63 (8–70)
Adenoid BCC 6 (10.3) 62.17 (52–72) 21.33 (15–30)
Infiltrative BCC 8 (13.9) 64.13 (47–81) 21.71 (12–35)*
Metatypic BCC 6 (10.3) 71.67 (45–85) 30.00 (10–70)
Nodular BCC 38 (65.5) 66.08 (21–87) 18.84 (8–50)
*Data missing for one case
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(LSAB+ System-HRP). Diaminobenzidine (DAB) served
as a substrate. The reactions were accompanied by a nega-
tive control. Subsequently, the preparations were counter-
stained with hematoxylin. All the antibodies and reagents
originated from DakoCytomation (Glostrup, Denmark).
Evaluation of IHC reactions. The intensity of MT expres-
sion in tumor cells was evaluated using the semi-quantita-
tive technique of Remmele and Stegner [22]. In every case,
the semi-quantitative immunoreactive score (IRS) of IHC
was calculated by multiplying the grade of scale defining pro-
portion of positive cells (0–4) by the degree of scale defining
intensity of color reaction (1–3), yielding a final score of 0 to
12. Intensity of Ki-67 antigen expression in tumor cells was
evaluated by the proportion of positive cells among tumor
cells as follows: 0 pts — no reaction; 1 pt — 1–10%; 2 pts —
11–25%; 3 pts — 26–50%; 4 pts — > 50% positive cells.
Statistical analysis. The obtained results were subjected to
statistical analysis using Prism 5.0 software (GraphPad, CA,
USA). Shapiro–Wilk test was applied to estimate the nor-
mality of distribution. Spearman’s correlation test, the
Kruskal–Wallis test, and the U test of Mann and Whitney
were used to compare the results. Differences were accept-
ed to be significant at p < 0.05.
Results
Cytoplasmatic/nuclear expression of MT and nucle-
ar expression of Ki-67 antigen were detected in all
examined cases of the studied basal cell carcinomas
(Figure 1). The highest intensity of MT-I/II expres-
sion was noted in adenoid BCC (5.17 ± 2.93), and
the lowest in metatypic BCC (4.33 ± 1.97). The most
pronounced expression of Ki-67 antigen was detect-
ed in the metatypic type of BCC (2.66 ± 1.03), and
the lowest intense one in nodular BCC (1.90 ± 0.89).
Expression intensities of the studied antigens for all
the examined cases and individual histopathologi-
cal types are presented in Table 2. No significant dif-
ferences were detected in MT-I/II expression or
Ki-67 expression between individual histological
types of BCC.
A positive correlation was demonstrated between
expression intensities of Ki-67 antigen and MT-I/II,
when the analysis took into account all 58 studied
cases of BCC (r = 0.26; p = 0.049; Figure 2A). Among
the studied subtypes, only the metatypic BCC sub-
type demonstrated a strong positive correlation be-
tween the two studied markers (MT-I/II and Ki-67)
(r = 0.85; p = 0.033; Figure 2B). In cases of the other
studied subtypes, no significant correlation was ob-
served between the studied markers.
Neither in the entire studied group, nor within
individual histopathological types, could any relation-
ship be detected between intensity of Ki-67 antigen
or MT-I/II expression on the one hand and diameter
of the tumor on the other.
Discussion
Since the mid-1990s, numerous studies have been
published related to expression of various antigens,
using e.g. IHC in skin carcinomas (mainly basal cell
carcinomas and spinocellular carcinomas). In these
studies, the authors have suggested that a variable ex-
pression of certain antigens in tumor cells (in the cell
nucleus or in the cytoplasm) or in cells of their sublay-
Figure 1. Cytoplasmatic/nuclear expression of MT-I/II (A)
and nuclear expression of Ki-67 antigen (B) in cells of BCC
Table 2. Expression of Ki-67 antigen and MT I/II in
histological subtypes of BCC
Ki-67 expression MT-I/II expression
(Mean ± SD) (Mean ± SD)
BCC 2.02 ± 0.93 4.50 ± 2.44
Adenoid BCC 2.17 ± 0.98 5.17 ± 2.93
Infiltrative BCC 2.00 ± 0.93 4.63 ± 1.60
Metatypic BCC 2.67 ± 1.03 4.33 ± 1.97
Nodular BCC 1.90 ± 0.89 4.40 ± 2.64
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er may correlate with the aggressiveness of the tumors,
providing important prognostic indices. Potential ad-
vantages have also been suggested of using IHC stud-
ies for easier differentiation between individual vari-
eties of BCC as well as between BCC and tumors of
a similar histomorphology (e.g. trichoepithelioma) [21,
23]. Results obtained in IHC studies conducted on these
types of tumors have frequently been equivocal.
Ionesco et al. performed a comparative analysis
of Ki-67, p53 and Bcl-2 antigen expression in two
groups: the more aggressive (metastatic) BCC tumors
and BCC of a benign course. They demonstrated no
significant differences between the groups in expres-
sion of the antigens [24]. On the other hand, Yerba-
kan et al. examined expression of Ki-67, CD31 and
epidermal growth factor receptor (EGFR) in groups
of BCC of variable aggressiveness. They found that
expression intensity of the mentioned antigens was
significantly higher in recurrent (i.e. more aggressive)
tumors, compared to primary tumors [25]. In a simi-
lar way, elevation in Ki-67 expression level was de-
tected by Healy et al. in BCC tumors which relapsed
after treatment, compared to tumors which were
cured [26]. The cellular proliferation characteristics
of various histological/clinical types of BCC were an-
alyzed by Horlock et al. using analysis of Ki-67 anti-
gen expression [27]. Their investigations showed that
intensity of proliferation measured by the level of
Ki-67 antigen expression was lower in the nodular and
micronodular types, and higher in scleroderma-like,
infiltrating and superficial BCC types, which is con-
sistent with our observations. According to the au-
thors, a correlation can be noted between higher ex-
pression of Ki-67 antigen and BCC variations of high-
er aggressiveness [27]. However, the authors seemed
to pay no attention to the significant aggressiveness
manifested by the micronodular type of BCC, mani-
festing in their hands low levels of Ki-67 antigen ex-
pression [4, 27]. Other proliferation markers, includ-
ing PCNA and Ki-67 in various types of BCC, were
also analyzed by Barrett et al. [28]. In this study, nu-
clear reaction of PCNA expression demonstrated
higher intensity than expression of Ki-67. PCNA was
manifested in less than 10% of BCC cells in the nod-
ular form, in more than 30% of cells in most tumors
in the scleroderma-like and infiltrating forms, and in
all tumors of the metatypic form [28]. Another study
which compared intensity of Ki-67 antigen expression
to depth of infiltration and histological type of BCC
demonstrated no relationship between the parame-
ters [29].
The results of the above-mentioned studies are
consistent with the results obtained by us showing no
differences between histological types of BCC and
tumor size. Janisson-Dargaud et al. also demonstrat-
ed no differences in the expression of proliferation
markers between recurrent and non-recurrent forms,
and only the frequency of aneuploidy proved to rep-
resent a prognostic factor linked to the risk of recur-
rence [30].
Rossen et al. analyzed levels of expression of
MT-I/II isoforms in BCC compared to normal epider-
mis and benign epidermal hypertrophy, including
basaloidal hypertrophy, covering solid fibromas [20].
Within normal epidermis, the expression of MT-I/II
was documented in cytoplasm of basal cells. A sim-
ilar form of MT expression was demonstrated in
a hypertrophic epidermis. Basaloidal proliferations,
as well as superficial and nodular forms of BCC,
demonstrated a decreased MT-I/II expression (in ap-
proximately 92% of the cases) [20]. Nevertheless, in
86% of cases of infiltrating BCC, increased expres-
sion of MT-I/II was demonstrated in neoplastic cells
[20]. Our results seem to confirm this observation.
The increased expression of MT-I/II in infiltrating
BCC type may be linked to an increase in clinical
malignancy. Interestingly, the metatypic BCC
showed comparable low MT-I/II expression with the
nodular BCC subtype, although the clinical course
of the latter is more benign. Moreover, in the
metatypic BCC, a weak correlation between MT-I/II
and Ki-67 antigen expression was noted, which may
Figure 2. Correlation between expression of MT-I/II and Ki-67 antigen in all the analyzed samples (A) and metatypic BCC (B)
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point to more pronounced pro-proliferative effects
of MT-I/II expression in this particular type. Although
metatypic BCC is regarded as an aggressive subtype
of BCC, it manifested the lowest MT-I/II expression
of the analyzed subtypes. We used IHC techniques to
determine MT-I/II expression, but recent studies have
shown that only particular MT-I/II isoforms may con-
tribute to cancer cell aggressiveness in some tumor
types [31–35]. In our study, we noted the highest Ki-67
antigen expression in this subtype. Other investiga-
tions related to the expression of MT in BCC, SCC
and healthy skin have also demonstrated an increased
level of MT-I/II expression in neoplastic tissues, which
may point to the role of MT-I/II in the progression
of basal cell carcinoma [21].
Even if our studies have failed to document sig-
nificant differences in the expression of Ki-67 anti-
gen and MT-I/II expression between various histolog-
ical types of BCC, its nodular type, manifesting the
most benign clinical course, has shown the lowest level
of Ki-67 antigen expression and a comparable expres-
sion of MT-I/II compared to the other histological
types. The positive correlation between expression of
Ki-67 and MT-I/II is worth accentuating, as it con-
firms the role of MT-I/II in the proliferation of neo-
plastic cells [6, 7, 13]. Moreover, in the metatypic va-
riety of BCC, the correlation coefficient has proven
to be very high despite the low number of examined
cases, which may indicate a significant effect of MT-I/II
on the proliferation process in this histological type
of BCC. In this study, MT-I/II and Ki-67 antigen ex-
pression did not correlate with tumor size, and the
absence of unequivocal data related to the risk of re-
currence does not permit the recognition of Ki-67
antigen or MT-I/II as prognostic factors in BCC, but
does give new insights into the biology of BCC. How-
ever, our study was limited by the small number of
particular cases of BCC subtypes. Therefore, our find-
ings cannot be generalized. Further studies are nec-
essary to confirm the role of MT-I/II in different BCC
subtypes.
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